Skip to main content

VIAS DE SEÑALIZACION PARA DESARROLLO Y MUERTE CELULAR EN EL MIOCARDIO: ESTUDIO INTEGRATIVO PARA SU COMPRENSION E IDENTIFICACION DE DIANAS TERAPEUTICAS.

SAF2013-44942-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2013
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre UNIVERSIDAD DE LLEIDA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Cardiac fibroblasts display endurance to ischemia, high ROS control and elevated respiration regulated by the JAK2/STAT pathway

  • Beà Tàrrega, Aida
  • García Valero, Juan
  • Irazoki, Andrea
  • Lana, Carlos
  • López-Lluch, Guillermo
  • Portero Otín, Manuel
  • Pérez Galán, Patricia
  • Inserte Igual, Javier
  • Ruiz Meana, Marisol
  • Zorzano, Antonio
  • Llovera i Tomàs, Marta
  • Sanchis, Daniel
Cardiovascular diseases are the leading cause of death globally and more than four out of five cases are due to ischemic events. Cardiac fibroblasts (CF) contribute to normal heart development and function, and produce the post-ischemic scar. Here, we characterize the biochemical and functional aspects related to CF endurance to ischemia-like conditions. Expression data mining showed that cultured human CF (HCF) express more BCL2 than pulmonary and dermal fibroblasts. In addition, gene set enrichment analysis showed overrepresentation of genes involved in the response to hypoxia and oxidative stress, respiration and Janus kinase (JAK)/Signal transducer and Activator of Transcription (STAT) signaling pathways in HCF. BCL2 sustained survival and proliferation of cultured rat CF, which also had higher respiration capacity and reactive oxygen species (ROS) production than pulmonary and dermal fibroblasts. This was associated with higher expression of the electron transport chain (ETC) and antioxidant enzymes. CF had high phosphorylation of JAK2 and its effectors STAT3 and STAT5, and their inhibition reduced viability and respiration, impaired ROS control and reduced the expression of BCL2, ETC complexes and antioxidant enzymes. Together, our results identify molecular and biochemical mechanisms conferring survival advantage to experimental ischemia in CF and show their control by the JAK2/STAT signaling pathway. The presented data point to potential targets for the regulation of cardiac fibrosis and also open the possibility of a general mechanism by which somatic cells required to acutely respond to ischemia are constitutively adapted to survive it., This research was funded by Ministerio de Ciencia eInnovación (MICINN), Gobierno de España, grant numbers SAF2013-44942-R and PID2019-104509RB-I00 to DS; Fundació La Marató TV3, grant number 20153810 to D.S; A.B. holds a contract from FundacióLa Marató TV3 and IRBLleida/Diputació de Lleida; Generalitat de Catalunya, (AGAUR) grant number 2017SGR996 to DS; PP-G Laboratory support wasobtained through research grants from MICINN(SAF2017/88275R) and CIBERONC (CB16/12/00334);JI and MR-M Laboratory support was obtained from Instituto de Salud Carlos III (ISCIII-FIS) grant PI19-01196; AZ Laboratory support was obtained throughresearch grants from MICINN (PID2019-106209RB-I00), and the Generalitat de Catalunya, (AGAUR) grant number 2017SGR1015. AZ is a recipient of an ICREA ‘Academia’ Award (Generalitat de Catalunya).We gratefully acknowledge institutional funding fromthe MINECO through the Centres of Excellence Severo Ochoa Award, and from the CERCA Programme of the Generalitat de Catalunya
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Genome Wide Meta-Analysis identifies common genetic signatures shared by heart function and Alzheimer’s disease

  • Sáez, María Eugenia
  • González-Pérez, Antonio
  • Hernández-Olasagarre, B.
  • Beà Tàrrega, Aida
  • Moreno-Grau, S.
  • de Rojas, Itziar
  • Monté-Rubio, G.
  • Orellana, Adelina
  • Valero, S.
  • Comella i Carnicé, Joan Xavier
  • Sanchis, Daniel
  • Ruiz, Agustín
Echocardiography has become an indispensable tool for the study of heart performance, improving the monitoring of individuals with cardiac diseases. Diverse genetic factors associated with echocardiographic measures have been previously reported. The impact of several apoptotic genes in heart development identified in experimental models prompted us to assess their potential association with human cardiac function. This study aimed at investigating the possible association of variants of apoptotic genes with echocardiographic traits and to identify new genetic markers associated with cardiac function. Genome wide data from different studies were obtained from public repositories. After quality control and imputation, a meta-analysis of individual association study results was performed. Our results confirmed the role of caspases and other apoptosis related genes with cardiac phenotypes. Moreover, enrichment analysis showed an over-representation of genes, including some apoptotic regulators, associated with Alzheimer’s disease. We further explored this unexpected observation which was confirmed by genetic correlation analyses. Our findings show the association of apoptotic gene variants with echocardiographic indicators of heart function and reveal a novel potential genetic link between echocardiographic measures in healthy populations and cognitive decline later on in life. These findings may have important implications for preventative strategies combating Alzheimer’s disease., General. Data collection and sharing for this project was partially funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. For the Alzheimer’s Disease Neuroimaging Initiative: Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp19content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf. The AddNeuroMed data are from a public-private partnership supported by EFPIA companies and SMEs as part of InnoMed (Innovative Medicines in Europe), an Integrated Project funded by the European Union of the Sixth Framework program priority FP6-2004-LIFESCIHEALTH-5. Clinical leads responsible for data collection are Iwona Kłoszewska (Lodz), Simon Lovestone (London), Patrizia Mecocci (Perugia), Hilkka Soininen (Kuopio), Magda Tsolaki (Thessaloniki), and Bruno Vellas (Toulouse), imaging leads are Andy Simmons (London), Lars-Olad Wahlund (Stockholm) and Christian Spenger (Zurich) and bioinformatics leads are Richard Dobson (London) and Stephen Newhouse (London). This dataset was downloaded from Synapse (https://doi.org/10.7303/syn2790911). Funding support for the Alzheimer’s Disease Genetics Consortium (ADGC) was provided through the NIA Division of Neuroscience (U01-AG032984). This study was downloaded from NIH dbGaP repository (phs000372.v1). The Coronary Artery Risk Development in Young Adults Study (CARDIA) is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the University of Alabama at Birmingham (N01-HC95095 & N01-HC48047), University of Minnesota (N01-HC48048), Northwestern University (N01-HC48049), and Kaiser Foundation Research Institute (N01-HC48050). This manuscript was not approved by CARDIA. The opinions and conclusions contained in this publication are solely those of the authors, and are not endorsed by CARDIA or the NHLBI and should not be assumed to reflect the opinions or conclusions of either. Genotyping for the CARDIA GENEVA cohort was supported by grant U01 HG004729 from the National Human Genome Research Institute. This study was downloaded from NIH dbGaP repository (phs000285.v3.p2). The Cardiovascular Heart Study (CHS) was supported by contracts HHSN268201200036C, HHSN268200800007C, N01-HC85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, and N01-HC-85239; grant numbers U01 HL080295 and U01 HL130014 from the National Heart, Lung, and Blood Institute, and R01 AG-023629 from the National Institute on Aging, with additional contribution from the National Institute of Neurological Disorders and Stroke. A full list of principal CHS investigators and institutions can be found at https://chs-nhlbi.org/pi. This manuscript was not prepared in collaboration with CHS investigators and does not necessarily reflect the opinions or views of CHS or the NHLBI. Support for the genotyping through the CARe Study was provided by NHLBI Contract N01-HC-65226. This study was downloaded from NIH dbGaP repository (phs000287.v5.p1). The Framingham Heart Study is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with Boston University (Contract No. N01-HC-25195 and HHSN268201500001I). This manuscript was not prepared in collaboration with investigators of the Framingham Heart Study and does not necessarily reflect the opinions or views of the Framingham Heart Study, Boston University, or NHLBI. “Funding for SHARe Affymetrix genotyping was provided by NHLBI Contract N02-HL64278. SHARe Illumina genotyping was provided under an agreement between Illumina and Boston University. Funding for Affymetrix genotyping of the FHS Omni cohorts was provided by Intramural NHLBI funds from Andrew D. Johnson and Christopher J. O’Donnell. This dataset was obtained from the NIH dbGaP repository (phs000007.v29.p10). The genotypic and associated phenotypic data used in the study, “Multi-Site Collaborative Study for Genotype-Phenotype Associations in Alzheimer’s Disease (GenADA)” were provided by the GlaxoSmithKline, R&D Limited. The datasets used for analyses described in this manuscript were obtained from NIH dbGaP repository (phs000219.v1.p1). The Mayo Clinic Alzheimer’s Disease Genetic Studies, led by Dr. Nilüfer Ertekin-Taner and Dr. Steven G. Younkin, Mayo Clinic, Jacksonville, FL using samples from the Mayo Clinic Study of Aging, the Mayo Clinic Alzheimer’s Disease Research Center, and the Mayo Clinic Brain Bank. Data collection was supported through funding by NIA grants P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949, NINDS grant R01 NS080820, CurePSP Foundation, and support from Mayo Foundation. This dataset was downloaded from Synapse (https://doi.org/10.7303/syn5550404). The MESA study was supported by contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the National Heart, Lung, and Blood Institute, and by grants UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from NCATS. The authors thank the other investigators, the staff, and the participants of the MESA study for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org. This dataset was obtained from the NIH dbGaP repository (phs000209.v6.p2). The Neocodex-Murcia study was funded by the Fundación Alzheimur (Murcia), the Ministerio de Educación y Ciencia (Gobierno de España), Corporación Tecnológica de Andalucía and Agencia IDEA (Consejería de Innovación, Junta de Andalucía). The Diabetes Research Laboratory, Biomedical Research Foundation. University Hospital Clínico San Carlos has been supported by CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM); CIBERDEM is an ISCIII Project. The ROS/MAP study data were provided by the Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago. Data collection was supported through funding by NIA grants P30AG10161, R01AG15819, R01AG17917, R01AG30146, R01AG36836, U01AG32984, U01AG46152, the Illinois Department of Public Health, and the Translational Genomics Research Institute. This dataset was downloaded from Synapse (https://doi.org/10.7303/syn3219045). The TGEN study was supported by Kronos Life Sciences Laboratories, the National Institute on Aging (Arizona Alzheimer’s Disease Center P30 AG19610, RO1 AG023193, Mayo Clinic Alzheimer’s Disease Center P50 AG16574, and Intramural Research Program), the National Alzheimer’s Coordinating Center (U01 AG016976), and the state of Arizona. TGEN investigators provided free access to genotype data to other researchers via Coriell Biorepositories (http://www.coriell.org). The results published here are in part based on data obtained from the AMP-AD Knowledge Portal accessed at https://doi.org/10.7303/syn2580853. D.S. research is supported by Grant 20153810 from Fundació La Marató de TV3 and Grant SAF2013-44942-R from the Ministerio de Economía y Competitividad (MINECO) and, with J.X.C., Grant 2009SGR-346 from the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) from the Government of Catalonia. A.B. has a predoctoral contract from Fundació La Marató de TV3. A.R. research is also supported by grants PI13/02434 and PI16/01861. Acción Estratégica en Salud, integrated in the Spanish National R&D&I Plan and financed by ISCIII (Instituto de Salud Carlos III)-Subdirección General de Evaluación and the European Regional Development Fund (ERDF – “A way to make Europe”), by Fundación banca “La Caixa” and Grifols SA (GR@ACE project). This work was also partly supported by the ADAPTED consortium, which has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115975. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations.
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

ENDOG Impacts on Tumor Cell Proliferation and Tumor Prognosis in the Context of PI3K/PTEN Pathway Status

  • Barés Junqué, Gisel
  • Beà Tàrrega, Aida
  • Hernández, Luís
  • Navaridas Fernández de Bobadilla, Raúl
  • Felip Nogués, Isidre
  • Megino-Luque, Cristina
  • Blasco Angulo, Natividad
  • Nadeu, Ferran
  • Campo, Elías
  • Llovera i Tomàs, Marta
  • Dolcet Roca, Xavier
  • Sanchis, Daniel
EndoG influences mitochondrial DNA replication and is involved in somatic cell proliferation. Here, we investigated the effect of ENDOG/Endog expression on proliferation in different tumor models. Noteworthy, ENDOG deficiency reduced proliferation of endometrial tumor cells expressing low PTEN/high p-AKT levels, and Endog deletion blunted the growth of PTEN-deficient 3D endometrial cultures. Furthermore, ENDOG silencing reduced proliferation of follicular thyroid carcinoma and glioblastoma cell lines with high p-AKT expression. High ENDOG expression was associated with a short time to treatment in a cohort of patients with chronic lymphocytic leukemia (CLL), a B-cell lymphoid neoplasm with activation of PI3K/AKT. This clinical impact was observed in the less aggressive CLL subtype with mutated IGHV in which high ENDOG and low PTEN levels were associated with worse outcome. In summary, our results show that reducing ENDOG expression hinders growth of some tumors characterized by low PTEN activity and high p-AKT expression and that ENDOG has prognostic value for some cancer types., This research was funded by Ministerio de Ciencia, Innovación y Universidades, Gobierno de España, grant numbers SAF2013-44942-R and PID2019-104509RB-I00 to D.S.; grant numbers SAF2016-80157-R and PID2019-104734RB-I00 to X.D.; Fundació La Marató TV3, grant number 20153810 to D.S. G.B. holds a contract from the University of Lleida; A.B. holds a contract from Fundació La Marató TV3 and IRBLleida/Diputació de Lleida; The Spanish Ministry of Science and Innovation (MICINN) through the Instituto de Salud Carlos III (ISCIII) International Cancer Genome Consortium for Chronic Lymphocytic Leukemia (ICGC-CLL Genome Project) to E.C.. Fundació La Marato de TV3 (201920-30) to L.H. Support Groups de Recerca AGAUR 2014-SGR-795 of the Generalitat de Catalunya to E.C.
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Cardiomyocyte hypertrophy induced by Endonuclease G deficiency requires reactive oxygen radicals accumulation and is inhibitable by the micropeptide humanin.

  • Blasco Angulo, Natividad
  • Cámara, Yolanda
  • Núñez, Estefanía
  • Beà Tàrrega, Aida
  • Barés Junqué, Gisel
  • Forné Izquierdo, Carles
  • Ruiz Meana, Marisol
  • Girón, Cristina
  • Barba, Ignasi
  • García Arumí, Elena
  • García Dorado, David
  • Vázquez, Jesús
  • Martí, Ramón
  • Llovera i Tomàs, Marta
  • Sanchis, Daniel
The endonuclease G gene (Endog), which codes for a mitochondrial nuclease, was identified as a determinant of cardiac hypertrophy. How ENDOG controls cardiomyocyte growth is still unknown. Thus, we aimed at finding the link between ENDOG activity and cardiomyocyte growth. Endog deficiency induced reactive oxygen species (ROS) accumulation and abnormal growth in neonatal rodent cardiomyocytes, altering the AKT-GSK3β and Class-II histone deacethylases (HDAC) signal transduction pathways. These effects were blocked by ROS scavengers. Lack of ENDOG reduced mitochondrial DNA (mtDNA) replication independently of ROS accumulation. Because mtDNA encodes several subunits of the mitochondrial electron transport chain, whose activity is an important source of cellular ROS, we investigated whether Endog deficiency compromised the expression and activity of the respiratory chain complexes but found no changes in these parameters nor in ATP content. MtDNA also codes for humanin, a micropeptide with possible metabolic functions. Nanomolar concentrations of synthetic humanin restored normal ROS levels and cell size in Endog-deficient cardiomyocytes. These results support the involvement of redox signaling in the control of cardiomyocyte growth by ENDOG and suggest a pathway relating mtDNA content to the regulation of cell growth probably involving humanin, which prevents reactive oxygen radicals accumulation and hypertrophy induced by Endog deficiency., This work was supported by Grant SAF2013–44942R from the Ministerio de Economía y Competitividad (MINECO) to DS, Grant 20153810 from Fundació La Marató de TV3 to DS, Program “Redes Temáticas de Investigación Cooperativa en Salud” (RETICS) Grants RD12/0042/0035, RD12/0042/0056 and RD12/0042/0021, Red de Investigación Cardiovascular (RIC) from the Instituto de Salud Carlos-III (ISCIII) to DS, DG-D and JV, Grant 2009SGR-346 from the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) from the Government of Catalonia to DS. AB is supported by Fundació La Marató de TV3 and GB is supported by a predoctoral contract from the Universitat de Lleida.
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Involvement of the mitochondrial nuclease EndoG in the regulation of cell proliferation through the control of reactive oxygen species

  • Blasco Angulo, Natividad
  • Beà Tàrrega, Aida
  • Barés Junqué, Gisel
  • Girón, Cristina
  • Navaridas Fernández de Bobadilla, Raúl
  • Irazoki, Andrea
  • López-Lluch, Guillermo
  • Zorzano, Antonio
  • Dolcet Roca, Xavier
  • Llovera i Tomàs, Marta
  • Sanchis, Daniel
The apoptotic nuclease EndoG is involved in mitochondrial DNA replication. Previous results suggested that, in addition to regulate cardiomyocyte hypertrophy, EndoG could be involved in cell proliferation. Here, by using in vivo and cell culture models, we investigated the role of EndoG in cell proliferation. Genetic deletion of Endog both in vivo and in cultured cells or Endog silencing in vitro induced a defect in rodent and human cell proliferation with a tendency of cells to accumulate in the G1 phase of cell cycle and increased reactive oxygen species (ROS) production. The defect in cell proliferation occurred with a decrease in the activity of the AKT/PKB-GSK-3β-Cyclin D axis and was reversed by addition of ROS scavengers. EndoG deficiency did not affect the expression of ROS detoxifying enzymes, nor the expression of the electron transport chain complexes and oxygen consumption rate. Addition of the micropeptide Humanin to EndoG-deficient cells restored AKT phosphorylation and proliferation without lowering ROS levels. Thus, our results show that EndoG is important for cell proliferation through the control of ROS and that Humanin can restore cell division in EndoG-deficient cells and counteracts the effects of ROS on AKT phosphorylation., This research was funded by Ministerio de Ciencia e Innovación, Gobierno de España, grant numbers SAF2013-44942-R and PID2019-104509RB-I00 to D.S. and SAF2016-80157-R to X.D.; Fundació La Marató, Catalunya, grant number 20153810 to D.S.; AGAUR, Generalitat de Catalunya, Catalunya, grant number 2014-SGR-1609 to D.S. G.B. holds a contract from the University of Lleida; A.B. contract has been funded by Fundació La Marató TV3 and Diputació de Lleida/IRBLleida.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Involvement of the mitochondrial nuclease EndoG in the regulation of cell proliferation through the control of reactive oxygen species

  • Blasco, Natividad
  • Beà, Aida
  • Barés, Gisel
  • Girón, Cristina
  • Navaridas, Raúl
  • Irazoki, Andrea
  • López-Lluch, Guillermo
  • Zorzano, Antonio
  • Dolcet, Xavier
  • Llovera, Marta
  • Sanchis, Daniel
© 2020 The Author(s)., The apoptotic nuclease EndoG is involved in mitochondrial DNA replication. Previous results suggested that, in addition to regulate cardiomyocyte hypertrophy, EndoG could be involved in cell proliferation. Here, by using in vivo and cell culture models, we investigated the role of EndoG in cell proliferation. Genetic deletion of Endog both in vivo and in cultured cells or Endog silencing in vitro induced a defect in rodent and human cell proliferation with a tendency of cells to accumulate in the G1 phase of cell cycle and increased reactive oxygen species (ROS) production. The defect in cell proliferation occurred with a decrease in the activity of the AKT/PKB-GSK-3β-Cyclin D axis and was reversed by addition of ROS scavengers. EndoG deficiency did not affect the expression of ROS detoxifying enzymes, nor the expression of the electron transport chain complexes and oxygen consumption rate. Addition of the micropeptide Humanin to EndoG-deficient cells restored AKT phosphorylation and proliferation without lowering ROS levels. Thus, our results show that EndoG is important for cell proliferation through the control of ROS and that Humanin can restore cell division in EndoG-deficient cells and counteracts the effects of ROS on AKT phosphorylation., This research was funded by Ministerio de Ciencia e Innovación, Gobierno de España, grant numbers SAF2013-44942-R and PID2019-104509RB-I00 to D.S. and SAF2016-80157-R to X.D.; Fundació La Marató, Catalunya, grant number 20153810 to D.S.; AGAUR, Generalitat de Catalunya, Catalunya, grant number 2014-SGR-1609 to D.S. G.B. holds a contract from the University of Lleida; A.B. contract has been funded by Fundació La Marató TV3 and Diputació de Lleida/IRBLleida.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cardiac fibroblasts display endurance to ischemia, high ROS control and elevated respiration regulated by the JAK2/STAT pathway

  • Beà, Aida
  • García Valero, Juan
  • Irazoki, Andrea
  • Lana, Carlos
  • López-Lluch, Guillermo
  • Portero-Otín, Manuel
  • Pérez-Galán, Patricia
  • Inserte, Javier
  • Ruiz-Meana, Marisol
  • Zorzano, Antonio
  • Llovera, Marta
  • Sanchis, Daniel
Cardiovascular diseases are the leading cause of death globally and more than four out of five cases are due to ischemic events. Cardiac fibroblasts (CF) contribute to normal heart development and function, and produce the post-ischemic scar. Here, we characterize the biochemical and functional aspects related to CF endurance to ischemia-like conditions. Expression data mining showed that cultured human CF (HCF) express more BCL2 than pulmonary and dermal fibroblasts. In addition, gene set enrichment analysis showed overrepresentation of genes involved in the response to hypoxia and oxidative stress, respiration and Janus kinase (JAK)/Signal transducer and Activator of Transcription (STAT) signaling pathways in HCF. BCL2 sustained survival and proliferation of cultured rat CF, which also had higher respiration capacity and reactive oxygen species (ROS) production than pulmonary and dermal fibroblasts. This was associated with higher expression of the electron transport chain (ETC) and antioxidant enzymes. CF had high phosphorylation of JAK2 and its effectors STAT3 and STAT5, and their inhibition reduced viability and respiration, impaired ROS control and reduced the expression of BCL2, ETC complexes and antioxidant enzymes. Together, our results identify molecular and biochemical mechanisms conferring survival advantage to experimental ischemia in CF and show their control by the JAK2/STAT signaling pathway. The presented data point to potential targets for the regulation of cardiac fibrosis and also open the possibility of a general mechanism by which somatic cells required to acutely respond to ischemia are constitutively adapted to survive it., This research was funded by Ministerio de Ciencia e Innovación (MICINN), Gobierno de España, grant numbers SAF2013-44942-R and PID2019-104509RB-I00 to DS; Fundació La Marató TV3, grant number 20153810 to D.S; A.B. holds a contract from Fundació La Marató TV3 and IRBLleida/Diputació de Lleida; Generalitat de Catalunya, (AGAUR) grant number 2017SGR996 to DS; PP-G Laboratory support was obtained through research grants from MICINN (SAF2017/88275R) and CIBERONC (CB16/12/00334); JI and MR-M Laboratory support was obtained from Instituto de Salud Carlos III (ISCIII-FIS) grant PI19-01196; AZ Laboratory support was obtained through research grants from MICINN (PID2019-106209RB-I00), and the Generalitat de Catalunya, (AGAUR) grant number 2017SGR1015. AZ is a recipient of an ICREA ‘Academia’ Award (Generalitat de Catalunya). We gratefully acknowledge institutional funding from the MINECO through the Centres of Excellence Severo Ochoa Award, and from the CERCA Programme of the Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cardiomyocyte hypertrophy induced by Endonuclease G deficiency requires reactive oxygen radicals accumulation and is inhibitable by the micropeptide humanin.

  • Blasco Angulo, Natividad
  • Cámara, Yolanda
  • Núñez, Estefanía
  • Beà Tàrrega, Aida
  • Barés Junqué, Gisel
  • Forné Izquierdo, Carles
  • Ruiz Meana, Marisol
  • Girón, Cristina
  • Barba, Ignasi
  • García Arumí, Elena
  • García Dorado, David
  • Vázquez, Jesús
  • Martí, Ramón
  • Llovera i Tomàs, Marta
  • Sanchis, Daniel
The endonuclease G gene (Endog), which codes for a mitochondrial nuclease, was identified as a determinant of cardiac hypertrophy. How ENDOG controls cardiomyocyte growth is still unknown. Thus, we aimed at finding the link between ENDOG activity and cardiomyocyte growth. Endog deficiency induced reactive oxygen species (ROS) accumulation and abnormal growth in neonatal rodent cardiomyocytes, altering the AKT-GSK3β and Class-II histone deacethylases (HDAC) signal transduction pathways. These effects were blocked by ROS scavengers. Lack of ENDOG reduced mitochondrial DNA (mtDNA) replication independently of ROS accumulation. Because mtDNA encodes several subunits of the mitochondrial electron transport chain, whose activity is an important source of cellular ROS, we investigated whether Endog deficiency compromised the expression and activity of the respiratory chain complexes but found no changes in these parameters nor in ATP content. MtDNA also codes for humanin, a micropeptide with possible metabolic functions. Nanomolar concentrations of synthetic humanin restored normal ROS levels and cell size in Endog-deficient cardiomyocytes. These results support the involvement of redox signaling in the control of cardiomyocyte growth by ENDOG and suggest a pathway relating mtDNA content to the regulation of cell growth probably involving humanin, which prevents reactive oxygen radicals accumulation and hypertrophy induced by Endog deficiency., This work was supported by Grant SAF2013–44942R from the Ministerio de Economía y Competitividad (MINECO) to DS, Grant 20153810 from Fundació La Marató de TV3 to DS, Program “Redes Temáticas de Investigación Cooperativa en Salud” (RETICS) Grants RD12/0042/0035, RD12/0042/0056 and RD12/0042/0021, Red de Investigación Cardiovascular (RIC) from the Instituto de Salud Carlos-III (ISCIII) to DS, DG-D and JV, Grant 2009SGR-346 from the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) from the Government of Catalonia to DS. AB is supported by Fundació La Marató de TV3 and GB is supported by a predoctoral contract from the Universitat de Lleida.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Genome Wide Meta-Analysis identifies common genetic signatures shared by heart function and Alzheimer’s disease

  • Sáez, María Eugenia
  • González-Pérez, Antonio
  • Hernández-Olasagarre, B.
  • Beà Tàrrega, Aida
  • Moreno-Grau, S.
  • de Rojas, Itziar
  • Monté-Rubio, G.
  • Orellana, Adelina
  • Valero, S.
  • Comella i Carnicé, Joan Xavier
  • Sanchis, Daniel
  • Ruiz, Agustín
Echocardiography has become an indispensable tool for the study of heart performance, improving the monitoring of individuals with cardiac diseases. Diverse genetic factors associated with echocardiographic measures have been previously reported. The impact of several apoptotic genes in heart development identified in experimental models prompted us to assess their potential association with human cardiac function. This study aimed at investigating the possible association of variants of apoptotic genes with echocardiographic traits and to identify new genetic markers associated with cardiac function. Genome wide data from different studies were obtained from public repositories. After quality control and imputation, a meta-analysis of individual association study results was performed. Our results confirmed the role of caspases and other apoptosis related genes with cardiac phenotypes. Moreover, enrichment analysis showed an over-representation of genes, including some apoptotic regulators, associated with Alzheimer’s disease. We further explored this unexpected observation which was confirmed by genetic correlation analyses. Our findings show the association of apoptotic gene variants with echocardiographic indicators of heart function and reveal a novel potential genetic link between echocardiographic measures in healthy populations and cognitive decline later on in life. These findings may have important implications for preventative strategies combating Alzheimer’s disease., General. Data collection and sharing for this project was partially funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. For the Alzheimer’s Disease Neuroimaging Initiative: Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp19content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf. The AddNeuroMed data are from a public-private partnership supported by EFPIA companies and SMEs as part of InnoMed (Innovative Medicines in Europe), an Integrated Project funded by the European Union of the Sixth Framework program priority FP6-2004-LIFESCIHEALTH-5. Clinical leads responsible for data collection are Iwona Kłoszewska (Lodz), Simon Lovestone (London), Patrizia Mecocci (Perugia), Hilkka Soininen (Kuopio), Magda Tsolaki (Thessaloniki), and Bruno Vellas (Toulouse), imaging leads are Andy Simmons (London), Lars-Olad Wahlund (Stockholm) and Christian Spenger (Zurich) and bioinformatics leads are Richard Dobson (London) and Stephen Newhouse (London). This dataset was downloaded from Synapse (https://doi.org/10.7303/syn2790911). Funding support for the Alzheimer’s Disease Genetics Consortium (ADGC) was provided through the NIA Division of Neuroscience (U01-AG032984). This study was downloaded from NIH dbGaP repository (phs000372.v1). The Coronary Artery Risk Development in Young Adults Study (CARDIA) is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the University of Alabama at Birmingham (N01-HC95095 & N01-HC48047), University of Minnesota (N01-HC48048), Northwestern University (N01-HC48049), and Kaiser Foundation Research Institute (N01-HC48050). This manuscript was not approved by CARDIA. The opinions and conclusions contained in this publication are solely those of the authors, and are not endorsed by CARDIA or the NHLBI and should not be assumed to reflect the opinions or conclusions of either. Genotyping for the CARDIA GENEVA cohort was supported by grant U01 HG004729 from the National Human Genome Research Institute. This study was downloaded from NIH dbGaP repository (phs000285.v3.p2). The Cardiovascular Heart Study (CHS) was supported by contracts HHSN268201200036C, HHSN268200800007C, N01-HC85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, and N01-HC-85239; grant numbers U01 HL080295 and U01 HL130014 from the National Heart, Lung, and Blood Institute, and R01 AG-023629 from the National Institute on Aging, with additional contribution from the National Institute of Neurological Disorders and Stroke. A full list of principal CHS investigators and institutions can be found at https://chs-nhlbi.org/pi. This manuscript was not prepared in collaboration with CHS investigators and does not necessarily reflect the opinions or views of CHS or the NHLBI. Support for the genotyping through the CARe Study was provided by NHLBI Contract N01-HC-65226. This study was downloaded from NIH dbGaP repository (phs000287.v5.p1). The Framingham Heart Study is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with Boston University (Contract No. N01-HC-25195 and HHSN268201500001I). This manuscript was not prepared in collaboration with investigators of the Framingham Heart Study and does not necessarily reflect the opinions or views of the Framingham Heart Study, Boston University, or NHLBI. “Funding for SHARe Affymetrix genotyping was provided by NHLBI Contract N02-HL64278. SHARe Illumina genotyping was provided under an agreement between Illumina and Boston University. Funding for Affymetrix genotyping of the FHS Omni cohorts was provided by Intramural NHLBI funds from Andrew D. Johnson and Christopher J. O’Donnell. This dataset was obtained from the NIH dbGaP repository (phs000007.v29.p10). The genotypic and associated phenotypic data used in the study, “Multi-Site Collaborative Study for Genotype-Phenotype Associations in Alzheimer’s Disease (GenADA)” were provided by the GlaxoSmithKline, R&D Limited. The datasets used for analyses described in this manuscript were obtained from NIH dbGaP repository (phs000219.v1.p1). The Mayo Clinic Alzheimer’s Disease Genetic Studies, led by Dr. Nilüfer Ertekin-Taner and Dr. Steven G. Younkin, Mayo Clinic, Jacksonville, FL using samples from the Mayo Clinic Study of Aging, the Mayo Clinic Alzheimer’s Disease Research Center, and the Mayo Clinic Brain Bank. Data collection was supported through funding by NIA grants P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949, NINDS grant R01 NS080820, CurePSP Foundation, and support from Mayo Foundation. This dataset was downloaded from Synapse (https://doi.org/10.7303/syn5550404). The MESA study was supported by contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the National Heart, Lung, and Blood Institute, and by grants UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from NCATS. The authors thank the other investigators, the staff, and the participants of the MESA study for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org. This dataset was obtained from the NIH dbGaP repository (phs000209.v6.p2). The Neocodex-Murcia study was funded by the Fundación Alzheimur (Murcia), the Ministerio de Educación y Ciencia (Gobierno de España), Corporación Tecnológica de Andalucía and Agencia IDEA (Consejería de Innovación, Junta de Andalucía). The Diabetes Research Laboratory, Biomedical Research Foundation. University Hospital Clínico San Carlos has been supported by CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM); CIBERDEM is an ISCIII Project. The ROS/MAP study data were provided by the Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago. Data collection was supported through funding by NIA grants P30AG10161, R01AG15819, R01AG17917, R01AG30146, R01AG36836, U01AG32984, U01AG46152, the Illinois Department of Public Health, and the Translational Genomics Research Institute. This dataset was downloaded from Synapse (https://doi.org/10.7303/syn3219045). The TGEN study was supported by Kronos Life Sciences Laboratories, the National Institute on Aging (Arizona Alzheimer’s Disease Center P30 AG19610, RO1 AG023193, Mayo Clinic Alzheimer’s Disease Center P50 AG16574, and Intramural Research Program), the National Alzheimer’s Coordinating Center (U01 AG016976), and the state of Arizona. TGEN investigators provided free access to genotype data to other researchers via Coriell Biorepositories (http://www.coriell.org). The results published here are in part based on data obtained from the AMP-AD Knowledge Portal accessed at https://doi.org/10.7303/syn2580853. D.S. research is supported by Grant 20153810 from Fundació La Marató de TV3 and Grant SAF2013-44942-R from the Ministerio de Economía y Competitividad (MINECO) and, with J.X.C., Grant 2009SGR-346 from the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) from the Government of Catalonia. A.B. has a predoctoral contract from Fundació La Marató de TV3. A.R. research is also supported by grants PI13/02434 and PI16/01861. Acción Estratégica en Salud, integrated in the Spanish National R&D&I Plan and financed by ISCIII (Instituto de Salud Carlos III)-Subdirección General de Evaluación and the European Regional Development Fund (ERDF – “A way to make Europe”), by Fundación banca “La Caixa” and Grifols SA (GR@ACE project). This work was also partly supported by the ADAPTED consortium, which has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115975. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

ENDOG Impacts on Tumor Cell Proliferation and Tumor Prognosis in the Context of PI3K/PTEN Pathway Status

  • Barés Junqué, Gisel
  • Beà Tàrrega, Aida
  • Hernández, Luís
  • Navaridas Fernández de Bobadilla, Raúl
  • Felip Nogués, Isidre
  • Megino-Luque, Cristina
  • Blasco Angulo, Natividad
  • Nadeu, Ferran
  • Campo, Elías
  • Llovera i Tomàs, Marta
  • Dolcet Roca, Xavier
  • Sanchis, Daniel
EndoG influences mitochondrial DNA replication and is involved in somatic cell proliferation. Here, we investigated the effect of ENDOG/Endog expression on proliferation in different tumor models. Noteworthy, ENDOG deficiency reduced proliferation of endometrial tumor cells expressing low PTEN/high p-AKT levels, and Endog deletion blunted the growth of PTEN-deficient 3D endometrial cultures. Furthermore, ENDOG silencing reduced proliferation of follicular thyroid carcinoma and glioblastoma cell lines with high p-AKT expression. High ENDOG expression was associated with a short time to treatment in a cohort of patients with chronic lymphocytic leukemia (CLL), a B-cell lymphoid neoplasm with activation of PI3K/AKT. This clinical impact was observed in the less aggressive CLL subtype with mutated IGHV in which high ENDOG and low PTEN levels were associated with worse outcome. In summary, our results show that reducing ENDOG expression hinders growth of some tumors characterized by low PTEN activity and high p-AKT expression and that ENDOG has prognostic value for some cancer types., This research was funded by Ministerio de Ciencia, Innovación y Universidades, Gobierno de España, grant numbers SAF2013-44942-R and PID2019-104509RB-I00 to D.S.; grant numbers SAF2016-80157-R and PID2019-104734RB-I00 to X.D.; Fundació La Marató TV3, grant number 20153810 to D.S. G.B. holds a contract from the University of Lleida; A.B. holds a contract from Fundació La Marató TV3 and IRBLleida/Diputació de Lleida; The Spanish Ministry of Science and Innovation (MICINN) through the Instituto de Salud Carlos III (ISCIII) International Cancer Genome Consortium for Chronic Lymphocytic Leukemia (ICGC-CLL Genome Project) to E.C.. Fundació La Marato de TV3 (201920-30) to L.H. Support Groups de Recerca AGAUR 2014-SGR-795 of the Generalitat de Catalunya to E.C.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cardiac fibroblasts display endurance to ischemia, high ROS control and elevated respiration regulated by the JAK2/STAT pathway

  • Beà Tàrrega, Aida
  • García Valero, Juan
  • Irazoki, Andrea
  • Lana, Carlos
  • López-Lluch, Guillermo
  • Portero Otín, Manuel
  • Pérez Galán, Patricia
  • Inserte Igual, Javier
  • Ruiz Meana, Marisol
  • Zorzano, Antonio
  • Llovera i Tomàs, Marta
  • Sanchis, Daniel
Cardiovascular diseases are the leading cause of death globally and more than four out of five cases are due to ischemic events. Cardiac fibroblasts (CF) contribute to normal heart development and function, and produce the post-ischemic scar. Here, we characterize the biochemical and functional aspects related to CF endurance to ischemia-like conditions. Expression data mining showed that cultured human CF (HCF) express more BCL2 than pulmonary and dermal fibroblasts. In addition, gene set enrichment analysis showed overrepresentation of genes involved in the response to hypoxia and oxidative stress, respiration and Janus kinase (JAK)/Signal transducer and Activator of Transcription (STAT) signaling pathways in HCF. BCL2 sustained survival and proliferation of cultured rat CF, which also had higher respiration capacity and reactive oxygen species (ROS) production than pulmonary and dermal fibroblasts. This was associated with higher expression of the electron transport chain (ETC) and antioxidant enzymes. CF had high phosphorylation of JAK2 and its effectors STAT3 and STAT5, and their inhibition reduced viability and respiration, impaired ROS control and reduced the expression of BCL2, ETC complexes and antioxidant enzymes. Together, our results identify molecular and biochemical mechanisms conferring survival advantage to experimental ischemia in CF and show their control by the JAK2/STAT signaling pathway. The presented data point to potential targets for the regulation of cardiac fibrosis and also open the possibility of a general mechanism by which somatic cells required to acutely respond to ischemia are constitutively adapted to survive it., This research was funded by Ministerio de Ciencia eInnovación (MICINN), Gobierno de España, grant numbers SAF2013-44942-R and PID2019-104509RB-I00 to DS; Fundació La Marató TV3, grant number 20153810 to D.S; A.B. holds a contract from FundacióLa Marató TV3 and IRBLleida/Diputació de Lleida; Generalitat de Catalunya, (AGAUR) grant number 2017SGR996 to DS; PP-G Laboratory support wasobtained through research grants from MICINN(SAF2017/88275R) and CIBERONC (CB16/12/00334);JI and MR-M Laboratory support was obtained from Instituto de Salud Carlos III (ISCIII-FIS) grant PI19-01196; AZ Laboratory support was obtained throughresearch grants from MICINN (PID2019-106209RB-I00), and the Generalitat de Catalunya, (AGAUR) grant number 2017SGR1015. AZ is a recipient of an ICREA ‘Academia’ Award (Generalitat de Catalunya).We gratefully acknowledge institutional funding fromthe MINECO through the Centres of Excellence Severo Ochoa Award, and from the CERCA Programme of the Generalitat de Catalunya
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Involvement of the mitochondrial nuclease EndoG in the regulation of cell proliferation through the control of reactive oxygen species

  • Blasco Angulo, Natividad
  • Beà Tàrrega, Aida
  • Barés Junqué, Gisel
  • Girón, Cristina
  • Navaridas Fernández de Bobadilla, Raúl
  • Irazoki, Andrea
  • López-Lluch, Guillermo
  • Zorzano, Antonio
  • Dolcet Roca, Xavier
  • Llovera i Tomàs, Marta
  • Sanchis, Daniel
The apoptotic nuclease EndoG is involved in mitochondrial DNA replication. Previous results suggested that, in addition to regulate cardiomyocyte hypertrophy, EndoG could be involved in cell proliferation. Here, by using in vivo and cell culture models, we investigated the role of EndoG in cell proliferation. Genetic deletion of Endog both in vivo and in cultured cells or Endog silencing in vitro induced a defect in rodent and human cell proliferation with a tendency of cells to accumulate in the G1 phase of cell cycle and increased reactive oxygen species (ROS) production. The defect in cell proliferation occurred with a decrease in the activity of the AKT/PKB-GSK-3β-Cyclin D axis and was reversed by addition of ROS scavengers. EndoG deficiency did not affect the expression of ROS detoxifying enzymes, nor the expression of the electron transport chain complexes and oxygen consumption rate. Addition of the micropeptide Humanin to EndoG-deficient cells restored AKT phosphorylation and proliferation without lowering ROS levels. Thus, our results show that EndoG is important for cell proliferation through the control of ROS and that Humanin can restore cell division in EndoG-deficient cells and counteracts the effects of ROS on AKT phosphorylation., This research was funded by Ministerio de Ciencia e Innovación, Gobierno de España, grant numbers SAF2013-44942-R and PID2019-104509RB-I00 to D.S. and SAF2016-80157-R to X.D.; Fundació La Marató, Catalunya, grant number 20153810 to D.S.; AGAUR, Generalitat de Catalunya, Catalunya, grant number 2014-SGR-1609 to D.S. G.B. holds a contract from the University of Lleida; A.B. contract has been funded by Fundació La Marató TV3 and Diputació de Lleida/IRBLleida.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cardiomyocyte hypertrophy induced by Endonuclease G deficiency requires reactive oxygen radicals accumulation and is inhibitable by the micropeptide humanin

  • Blasco, Natividad
  • Cámara, Yolanda|||0000-0003-2458-6942
  • Nuñez, Estefania|||0000-0002-0876-1264
  • Beà, Aida|||0000-0002-9733-4618
  • Barés, Gisel
  • Forne, Carles|||0000-0002-8133-3274
  • Ruíz-Meana, Marisol
  • Girón, Cristina
  • Barba, Ignasi|||0000-0001-9886-3776
  • García Arumí, Elena|||0000-0003-1848-005X
  • García-Dorado, David|||0000-0002-1126-1279
  • Vázquez, Jesús|||0000-0003-1461-5092
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Llovera, Marta
  • Sanchis, Daniel
The endonuclease G gene (Endog), which codes for a mitochondrial nuclease, was identified as a determinant of cardiac hypertrophy. How ENDOG controls cardiomyocyte growth is still unknown. Thus, we aimed at finding the link between ENDOG activity and cardiomyocyte growth. Endog deficiency induced reactive oxygen species (ROS) accumulation and abnormal growth in neonatal rodent cardiomyocytes, altering the AKT-GSK3β and Class-II histone deacethylases (HDAC) signal transduction pathways. These effects were blocked by ROS scavengers. Lack of ENDOG reduced mitochondrial DNA (mtDNA) replication independently of ROS accumulation. Because mtDNA encodes several subunits of the mitochondrial electron transport chain, whose activity is an important source of cellular ROS, we investigated whether Endog deficiency compromised the expression and activity of the respiratory chain complexes but found no changes in these parameters nor in ATP content. MtDNA also codes for humanin, a micropeptide with possible metabolic functions. Nanomolar concentrations of synthetic humanin restored normal ROS levels and cell size in Endog -deficient cardiomyocytes. These results support the involvement of redox signaling in the control of cardiomyocyte growth by ENDOG and suggest a pathway relating mtDNA content to the regulation of cell growth probably involving humanin, which prevents reactive oxygen radicals accumulation and hypertrophy induced by Endog deficiency.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genome Wide Meta-Analysis identifies common genetic signatures shared by heart function and Alzheimer's disease

  • Sáez, María Eugenia|||0000-0001-9299-2534
  • González-Pérez, A.
  • Hernández-Olasagarre, B.
  • Beà, Aida|||0000-0002-9733-4618
  • Moreno-Grau, Sonia
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Monté-Rubio, Gemma C.|||0000-0002-3532-2224
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Valero, S.
  • Comella i Carnicé, Joan Xavier|||0000-0002-6218-0786
  • Sanchís, D.
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
Echocardiography has become an indispensable tool for the study of heart performance, improving the monitoring of individuals with cardiac diseases. Diverse genetic factors associated with echocardiographic measures have been previously reported. The impact of several apoptotic genes in heart development identified in experimental models prompted us to assess their potential association with human cardiac function. This study aimed at investigating the possible association of variants of apoptotic genes with echocardiographic traits and to identify new genetic markers associated with cardiac function. Genome wide data from different studies were obtained from public repositories. After quality control and imputation, a meta-analysis of individual association study results was performed. Our results confirmed the role of caspases and other apoptosis related genes with cardiac phenotypes. Moreover, enrichment analysis showed an over-representation of genes, including some apoptotic regulators, associated with Alzheimer's disease. We further explored this unexpected observation which was confirmed by genetic correlation analyses. Our findings show the association of apoptotic gene variants with echocardiographic indicators of heart function and reveal a novel potential genetic link between echocardiographic measures in healthy populations and cognitive decline later on in life. These findings may have important implications for preventative strategies combating Alzheimer's disease.